http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2749038-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a957bad53e60bfbafbc229f94ae27a5a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2017-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dab0a99a585d750457aef09c77f819ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5749a10ba6a2e665fb25e53c8882ad9f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fe6c69951d7c9721e992e793a4e3493 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_461543487f433d69cbc3314243dea589 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44f81b4a74d5dfd87d2267682b2dc2e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_413b8a4ab30e18479566f36320a4e475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed6ca97e3a21ca6d1e5cfd675fa8eaf5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bacb667709680d253f86736483a33ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6122ea69f825099e10016623de24dd02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c15637e422fa9ece2493094fc56fe0b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b05638242b60f7828e2276ddec15e49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b805f6c6d959bb9dc1ee6c7054b127ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edb46c745cd95f494d84e36c3c249265 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_194cc752dcad93f56d26a07a61759b8c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2e629b8ad65def3559bdea4f939af0e |
| publicationDate | 2021-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2749038-C2 |
| titleOfInvention | Substituted pyrrolo [2,3-d] pyridazin-4-ones and pyrazolo [3,4-d] pyridazin-4-ones as proteinkinase inhibitors |
| abstract | FIELD: pharmaceutical compounds.SUBSTANCE: invention relates to a compound of Formula (II) or a pharmaceutically acceptable salt thereof, which can find use as inhibitors of Bruton's tyrosine kinase (BTK). In Formula (II), ring Q1 is selected from aryl and heteroaryl, where aryl and heteroaryl are each unsubstituted or substituted with at least one substituent independently selected from RX, where aryl is phenyl or naphthyl, where heteroaryl is a 5-6 membered aromatic, monocyclic ring containing from 1 to 2 heteroatoms selected from N, with the remaining ring atoms being carbon; ring Q2 is selected from heterocyclyl, where heterocyclyl is a single aliphatic ring with 4-6 ring atoms containing 1 to 2 heteroatoms selected from N; L is selected from -O-, -N(RA1)C(O)- and -C(O)N(RA1)-; W is -C(O)-; Y is selected from N and CR6; R1is hydrogen; each R2is hydrogen; R3is hydrogen; R5is selected from hydrogen and C1-10alkyl; R4is selected from hydrogen, C1-10alkyl, heterocyclyl or heterocyclyl-C1-4alkyl, where heterocyclyl is unsubstituted or substituted by at least one substituent independently selected from RX, where heterocyclyl is a single aliphatic ring with 4-5 ring atoms containing 1 heteroatom selected from N; or R3and R4, taken together, form a bond; R6is hydrogen; each RA1is hydrogen; each RXis independently selected from hydrogen, C1-10alkyl, halogen, CN and NO2; n is 0; p is 0. The invention also relates to a pharmaceutical composition for inhibiting the kinase activity of Bruton's tyrosine kinase (BTK), containing an effective amount of the said compound and at least one pharmaceutically acceptable carrier, and to a method of treating, ameliorating or preventing a condition that responds to BTK inhibition, comprising administering to a subject in need of such treatment, an effective amount of the said compound.EFFECT: invention can be used for treatment of an inflammatory and/or autoimmune condition.34 cl, 2 tbl, 117 ex(II) |
| priorityDate | 2016-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 460.